| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Mucin 63 mg and xylitol 39 mg oromucosal lozenge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xylitol (substance) |
Inferred relationship |
Some |
|
| Product containing xylitol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Xylitol (substance) |
Inferred relationship |
Some |
1 |
| Product containing mucin and xylitol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Xylitol (substance) |
Inferred relationship |
Some |
2 |
| Product containing only mucin and xylitol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Xylitol (substance) |
Inferred relationship |
Some |
2 |
| Product containing only xylitol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Xylitol (substance) |
Inferred relationship |
Some |
1 |
| Product containing mucin and xylitol in oromucosal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Xylitol (substance) |
Inferred relationship |
Some |
2 |
| Mucin 63 mg and xylitol 39 mg oromucosal lozenge |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Xylitol (substance) |
Inferred relationship |
Some |
2 |
| Mucin 63 mg and xylitol 39 mg oromucosal lozenge |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Xylitol (substance) |
Inferred relationship |
Some |
2 |
| Product containing only mucin and xylitol in oromucosal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Xylitol (substance) |
Inferred relationship |
Some |
2 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]